SynthesisClinical research in cardiology : official journal of the German Cardiac Society2006
Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis.
Synthesis in Clinical research in cardiology : official journal of the German Cardiac Society, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 68 citations in OpenAlex.
- Trial
- Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.Clinical journal of the American Society of Nephrology : CJASN · 2011 · on this mapTrial
- Optimal Medical Therapy Targeting Lipids and Inflammation for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention.Journal of clinical medicine · 2025Review
- Skeletal Muscle and Cardiovascular Health.Advances in experimental medicine and biology · 2025Review
- First Iranian guidelines for the diagnosis, management, and treatment of hyperlipidemia in adults.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2024Article
- Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023Review
- A Jordanian Multidisciplinary Consensus Statement on the Management of Dyslipidemia.Journal of clinical medicine · 2023Review
- Novel Target Study to Cure Cardiovascular Disease regarding Proprotein Converse Subtilisin/Kexin Type 9.BioMed research international · 2022Article
- Safety and efficacy of alirocumab: A meta analysis of 12 randomized controlled trials.Journal of family medicine and primary care · 2019Article
- Lunasin functionally enhances LDL uptake via inhibiting PCSK9 and enhancing LDLR expressionOncotarget · 2017Article
- Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.Acta pharmacologica Sinica · 2017Review
- Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk.Clinical research in cardiology : official journal of the German Cardiac Society · 2016Article
- Lipid lowering with PCSK9 inhibitors.Nature reviews. Cardiology · 2014Review
- Epidemiology and prevention of stroke: a worldwide perspective.Expert review of neurotherapeutics · 2012Review
- Differences in statin usage and target-goal achievement between departments at the same hospital.PloS one · 2012Article
- Trends in age-standardised and age-specific mortality from ischaemic heart disease in Germany.Clinical research in cardiology : official journal of the German Cardiac Society · 2010Article
- Regional variation of mortality from ischemic heart disease in Germany from 1998 to 2007.Clinical research in cardiology : official journal of the German Cardiac Society · 2010Article
- [Rosuvastatin for primary prevention of vascular events : JUPITER trial (Justification for the Use of statins in Prevention: an Intervention Trial Evaluation Rosuvastatin).]Der Internist · 2010Article
- The year in Clinical Research in Cardiology.Clinical research in cardiology : official journal of the German Cardiac Society · 2009Article
- Highlights of the hotline sessions presented at the scientific sessions 2008 of the American Heart Association.Clinical research in cardiology : official journal of the German Cardiac Society · 2009Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A recent meta-analysis of the Cholesterol Treatment Trialists' (CTT) Collaboration comes to the clear conclusion that a reduction in LDL-C using statins of 1 mmol/l (39 mg/dl) leads to a decrease in overall mortality by 12%, in coronary mortality by 19% and in the incidence of strokes by 17%, independent of the LDL-C level prior to the start of treatment. We conducted a systematic review retrieving 18 studies with a total of 116,343 [corrected] participants. Differences in average LDL-C reductions between the intervention and control groups during the follow-up and relative risks according to different clinical endpoints were extracted from the original publications. Metaregression analyses showed that reduction in LDL-C accounted for more than 75% of the variance in risk reductions for overall mortality and cardiovascular endpoints. On the basis of our estimates, a reduction in LDL-C of 1 mmol/l (39 mg/dl) leads to reductions in overall mortality, coronary mortality, incidence of non-fatal myocardial infarction, the combination of coronary mortality and non-fatal myocardial infarction, stroke and any vascular event by 15% (95% CI: 11-20%), 24% (95% CI: 20-28%), 27% (95% CI: 20-32%), 25% (95% CI: 22-29%), 24% (18-29%) and 22% (95% CI: 19-26%), respectively. We conclude that the extent to which statins lower LDL-C is strongly related to the improvement of clinical outcomes achieved by this class of drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.